{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T17:41:16Z","timestamp":1773769276091,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jfma.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T22:15:44Z","timestamp":1608156944000},"page":"1676-1685","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B"],"prefix":"10.1016","volume":"120","author":[{"given":"I-Cheng","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Wei","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keng-Hsin","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuei-Chuan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Chih","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jfma.2020.12.001_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"10.1016\/j.jfma.2020.12.001_bib2","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","article-title":"Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis","volume":"156","author":"Yeo","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S2468-1253(18)30308-X","article-title":"Spontaneous loss of surface antigen among adults living with chronic hepatitis B virus infection: a systematic review and pooled meta-analyses","volume":"4","author":"Zhou","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.07.057","article-title":"Development of direct-acting antiviral and host-targeting agents for treatment of hepatitis B virus infection","volume":"156","author":"Xia","year":"2019","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.jfma.2020.12.001_bib8","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa040431","article-title":"Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B","volume":"351","author":"Marcellin","year":"2004","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jfma.2020.12.001_bib9","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","article-title":"Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a","volume":"136","author":"Marcellin","year":"2009","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib10","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12072-012-9343-x","article-title":"Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients","volume":"7","author":"Marcellin","year":"2013","journal-title":"Hepatol Int"},{"issue":"7","key":"10.1016\/j.jfma.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/infdis\/jiy272","article-title":"Incidence and predictors of HBsAg loss after peginterferon therapy in HBeAg-negative chronic hepatitis B: a multicenter, long-term follow-up study","volume":"218","author":"Lee","year":"2018","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib12","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jhep.2009.12.015","article-title":"A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B","volume":"52","author":"Tan","year":"2010","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hep.28282","article-title":"Indoleamine-2,3-dioxygenase as an effector and an indicator of protective immune responses in patients with acute hepatitis B","volume":"63","author":"Yoshio","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1053\/j.gastro.2014.06.043","article-title":"Roles for chemokines in liver disease","volume":"147","author":"Marra","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jfma.2020.12.001_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1084\/jem.20151218","article-title":"Interferon-gamma facilitates hepatic antiviral T cell retention for the maintenance of liver-induced systemic tolerance","volume":"213","author":"Zeng","year":"2016","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.jfma.2020.12.001_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076798","article-title":"CXCL9 associated with sustained virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy: a pilot study","volume":"8","author":"Lee","year":"2013","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/apt.13447","article-title":"Serum interferon-inducible protein 10 levels predict hepatitis B s antigen seroclearance in patients with chronic hepatitis B","volume":"43","author":"Wong","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jfma.2020.12.001_bib18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jhep.2013.01.029","article-title":"Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B","volume":"58","author":"Sonneveld","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib19","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"issue":"32","key":"10.1016\/j.jfma.2020.12.001_bib21","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001341","article-title":"Durability of nucleos(t)ide analogues treatment in patients with chronic hepatitis B","volume":"94","author":"Lee","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.001_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058071","article-title":"IL28B polymorphism correlates with active hepatitis in patients with HBeAg-negative chronic hepatitis B","volume":"8","author":"Lee","year":"2013","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jfma.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/ijc.28311","article-title":"Serum interferon gamma level predicts recurrence in hepatocellular carcinoma patients after curative treatments","volume":"133","author":"Lee","year":"2013","journal-title":"Int J Canc"},{"issue":"3","key":"10.1016\/j.jfma.2020.12.001_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"10.1016\/j.jfma.2020.12.001_bib25","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/hep.22500","article-title":"Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C","volume":"48","author":"Zeremski","year":"2008","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jfma.2020.12.001_bib26","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1111\/j.1572-0241.2002.07054.x","article-title":"Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease","volume":"97","author":"Apolinario","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.jfma.2020.12.001_bib27","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1084\/jem.194.12.1755","article-title":"Blocking chemokine responsive to gamma-2\/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in\u00a0vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes","volume":"194","author":"Kakimi","year":"2001","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.jfma.2020.12.001_bib28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cld.2016.06.002","article-title":"Interferon treatment for hepatitis B","volume":"20","author":"Konerman","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jfma.2020.12.001_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2017.07.013","article-title":"Viral minority variants in the core promoter and precore region identified by deep sequencing are associated with response to peginterferon and adefovir in HBeAg negative chronic hepatitis B patients","volume":"145","author":"Jansen","year":"2017","journal-title":"Antivir Res"},{"issue":"8","key":"10.1016\/j.jfma.2020.12.001_bib30","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nri.2016.69","article-title":"Immune responses and immunopathology in acute and chronic viral hepatitis","volume":"16","author":"Shin","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"1 Suppl","key":"10.1016\/j.jfma.2020.12.001_bib31","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.001_bib32","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jhep.2012.09.029","article-title":"Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B","volume":"58","author":"Micco","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/1753425917714854","article-title":"Decrease of CD69 levels on TCR Valpha7.2(+)CD4(+) innate-like lymphocytes is associated with impaired cytotoxic functions in chronic hepatitis B virus-infected patients","volume":"23","author":"Yong","year":"2017","journal-title":"Innate Immun"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jfma.2020.12.001_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jfma.2020.12.001_bib36","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/hep.27323","article-title":"Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections","volume":"61","author":"Rehermann","year":"2015","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jfma.2020.12.001_bib37","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jhep.2011.12.032","article-title":"Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis","volume":"56","author":"Penna","year":"2012","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2020.12.001_bib38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jhep.2013.08.020","article-title":"Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy","volume":"60","author":"Tan","year":"2014","journal-title":"J Hepatol"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620305982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664620305982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T14:44:25Z","timestamp":1760539465000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664620305982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0929664620305982"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2020.12.001","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Formosan Medical Association. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}